Post-traumatic stress disorder (PTSD) is a condition with limited effective therapeutic options to date, where 5-HT2A receptor agonists show promise for enhancing cortical plasticity in the brain and ...
(NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ...
CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback